China's Changing Reimbursement Landscape Reshapes Pharma Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's prescription drugs market has seen a slowdown in growth in large cities due to implementation of government pilot reimbursement projects that could be adopted nationwide, according to a Sept. 27 Citi report
You may also be interested in...
China Health Insurance: As Funding, Expenditure Grow, How Will Pharma Companies Make Out?
The outflow growth rate for China’s national insurance fund has increased faster than inflow since China implemented health care reforms, but the government managed to reverse the trend last year through cost-containment measures. PharmAsia News takes a closer look at how those actions might impact pharma companies.
China Health Insurance: As Funding, Expenditure Grow, How Will Pharma Companies Make Out?
The outflow growth rate for China’s national insurance fund has increased faster than inflow since China implemented healthcare reforms, but the government managed to reverse the trend last year through cost-containment measures. PharmAsia News takes a closer look at how those actions might impact pharma companies.
Pharma Industry Growth Slower In China, But Smaller Cities Still Growing
China’s pharmaceutical industry slowed last year, especially domestic companies, according to IMS. But MNCs also saw slower growth from price cuts.